Sociedad Americana de Hirudoterapia

Production and evaluation of recombinant hirudin

Basic science / preclinical published in Seminars in thrombosis and hemostasis (1989)

Última actualización: March 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Desarrollo de fármacosGenómica y proteómicaFarmacología salivalEnsayos clínicosCourtney M et al. · Seminars in thrombosis and hemostasis, 1989

Abstract

Hirudin, a 65 amino acid polypeptide form the medicinal leech, is an extremely efficient and specific thrombin inhibitor whose therapeutic potential has been demonstrated in a number of animal models. We have developed protocols for the production of recombinant hirudin by secretion from S. cerevisiae and carried out a full biologic evaluation of the purified product. These studies showed that natural and recombinant hirudin was similar in structure and in biologic function in vitro. Moreover, the recombinant protein displayed strong antithrombotic activity in several experimental thrombosis models in vivo, confirming the molecule's promise in the therapy of thrombotic disorders.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAmino Acid SequenceAnimalsCloning, MolecularEscherichia coliGene ExpressionHirudin TherapyHirudinsMolecular Sequence DataRecombinant ProteinsSaccharomyces cerevisiaeThrombosis

Resumen

Hirudin, a 65 amino acid polypeptide form the medicinal leech, is an extremely efficient and specific thrombin inhibitor whose therapeutic potential has been demonstrated in a number of animal models.

Por qué esto importa para la hirudoterapia

Relevant to the development and clinical application of leech-derived pharmaceutical compounds.

Citación

Production and evaluation of recombinant hirudin.

Courtney M et al. · Seminars in thrombosis and hemostasis, 1989

Contexto clínico relacionado

Añadido a la biblioteca ASH: March 18, 2026 · Última actualización del sitio: March 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.

Production and evaluation of recombinant hirudin | ASH